Venture Capital investing in companies solving big life science problems with deep tech

Joined December 2017
15 Photos and videos
Pinned Tweet
30 Sep 2024
We're proud to announce DCVC Bio III: $400 million in fresh capital to support great scientific teams with boundary-pushing ideas for curing disease, extending health-spans, enabling healthy food at lower cost and climate impact, and more! bit.ly/3ZRmdpo

4
7
837
DCVC Bio retweeted
š‚šØš§šÆšžš«š šžš§šœšž š…šØš«š®š¦: Chicago based Grove Biopharma has engineered a technology, Bionic Biologics, that it hopes will give its therapies the versatility of biologics in a small molecule format. #ConvergenceForum
2
5
1,136
Working on hard problems is what @Solu_Tx is working on and has been recognized with #FDA #FastTrackDesignation in #CMML 🄳
We are proud to announce that STX-0712, our Phase 1 CCR2-CyTACā„¢ program in development for patients with resistant/refractory #CMML, has received FDA Fast Track designation. For more information, see our press release: cdn.prod.website-files.com/6…
75
DCVC Bio retweeted
Gene therapy is moving from promise to precision. Latus Bio added a $43M Series A extension from @8vc, @DCVCBio, and Hatch BioFund, bringing the round to $97M. P. Peter Ghoroghchian is building an AI-enabled platform focused on precision AAV delivery for neurological disease. The next biotech edge will come from pairing better vectors with better computational judgment.
1
1
1
98
At @DCVCBio, we see a need for a massive rein­vest­ment in the search for drugs that safely lessen anxiety, including existing compounds that have been shelved by big pharma companies. More on our thinking in 🧵
1
3
2
403
RNA- and DNA-based treatments (gene/cell therapy) have high upfront costs but are curative and more economical than chronic care. Regulators should work with insurers and manufacturers to cover costs and introduce new business models, like gradual payment plans. More in 🧵
1
1
1
256
We’re seeing aĀ new wave of gene therapy companies developing exquisitely customized viral vectors other advanced techniques that can deliver therapeutic genes to the body with far more specificity and at much lower doses and cost than before. šŸ‘‡ dcvc.com/news-insights/deep-…
1
382
In the @WSJ, our friend @crisman_ryan, co-founder of @UmojaBiopharma, offers a beautiful example of basic research meandering through labs over decades, then providing learnings that help us reset the immune systems of leukemia autoimmune patients: on.wsj.com/4aKcN4P
71
DCVC Bio retweeted
15 Oct 2025
Orca-T, our investigational allogeneic T-cell immunotherapy, is a finalist in the Biotech Innovation category of the Fierce Innovation Awards: Life Sciences Edition 2025! This award recognizes the companies and innovations pushing science forward to transform the field of life sciences. We're proud of the work we do on behalf of patients, and honored to be included. To learn more: orcabio.com/ #FierceLifeSciencesAwards and #FierceInnovationAwards
1
2
1
355
DCVC Bio retweeted
6 Oct 2025
Today, Orca Bio announced the FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Orca-T to treat hematological malignancies. Read more in the press release: bit.ly/4q1Uzkw #celltherapy #hematology #oncology
1
4
1,309
DCVC Bio retweeted
Augmented RNA reality is emerging! @creyonbio has the ability to programĀ­matĀ­iĀ­cally engineer knowably safe and effective siRNAs, ASOs, and other oligo therapies to unlock aĀ huge range of therapeutic advancesšŸ‘‡ dcvc.com/news-insights/creyo…
1
3
208
DCVC Bio retweeted
23 Apr 2025
Creyon Bio names Serge Messerlian as CEO and appoints Kiersten Stead, PhD, to the Board. With revitalized leadership & AI-powered oligo tech, we're advancing therapies in CNS, neuromuscular, & immunologic diseases. creyonbio.com/latest-news/ #BiotechNews #AIinHealthcare
1
2
178